Corticotroph tumour progression 37 years after bilateral adrenalectomy with temozolomide-naive response to pembrolizumab
Edward Mignone, Luke Ephraums, Ian Chapman, Esther Quick, Sunita M C De Sousa, Jui Ho · 2026
Read Corticotroph tumour progression 37 years after bilateral adrenalectomy with temozolomide-naive response to pembrolizumab by Edward Mignone, Luke Ephraums, Ian Chapman, Esther Quick, Sunita M C De Sousa, Jui Ho (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13615845.txt.
Description
Edward Mignone and co-authors report a pituitary tumour that grew again thirty-seven years after surgery, in a 2026 case paper. The patient had both adrenal glands removed for Cushing disease, a hormone disorder. Tumour growth after that surgery usually appears within ten years, so such a late return is among the latest recorded.
Profiling of the tumour showed an aggressive pattern, with several gene losses and gains and a growth index of ten percent. A marker that often predicts response to immune therapy was absent. Yet a checkpoint inhibitor drug, given for a separate skin cancer, brought a fast and lasting fall in hormone levels and tumour size. The authors draw three lessons: follow-up after adrenal surgery should last for life, profiling can guide care, and immune therapy may work even without that marker.
Catalog record
| CREATOR | Edward Mignone, Luke Ephraums, Ian Chapman, Esther Quick, Sunita M C De Sousa, Jui Ho |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |